Phosphodiesterases and their inhibitors /

Phosphodiesterases and their inhibitors /

Λεπτομέρειες βιβλιογραφικής εγγραφής
Άλλοι συγγραφείς: Liras, Spiros (Επιμελητής έκδοσης), Bell, Andrew S. (Επιμελητής έκδοσης)
Μορφή: Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Weinheim an der Bergstrasse, Germany : Wiley-VCH, 2014.
Σειρά:Methods and principles in medicinal chemistry ; Volume 61.
Θέματα:
Cyclic nucleotide phosphodiesterases.
Phosphodiesterases > Inhibitors.
Phosphodiesterases > Inhibitors > Therapeutic use.
Nucleotides, Cyclic > physiology.
Phosphodiesterase Inhibitors > therapeutic use.
Phosphoric Diester Hydrolases > physiology.
Phosphoric Diester Hydrolases.
MEDICAL > Physiology.
SCIENCE > Life Sciences > Human Anatomy & Physiology.
Phosphodiesterase Inhibitors > chemistry.
Electronic books.
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 06301nam a2200913 4500
001 ocn878141373
003 OCoLC
005 20170124071838.8
006 m o d
007 cr cn|||||||||
008 140325t20142014gw a ob 001 0 eng d
040 |a E7B  |b eng  |e rda  |e pn  |c E7B  |d N$T  |d YDXCP  |d DG1  |d CDX  |d EBLCP  |d IDEBK  |d SFB  |d DEBSZ  |d COO  |d DEBBG  |d OCLCQ  |d CASUM  |d GrThAP 
019 |a 874321908  |a 881423826  |a 961577287  |a 962694307 
020 |a 9783527682355  |q (electronic bk.) 
020 |a 352768235X  |q (electronic bk.) 
020 |a 9783527682348  |q (electronic bk.) 
020 |a 3527682341  |q (electronic bk.) 
020 |a 3527332197 
020 |a 9783527332199 
020 |a 9781306531955 
020 |a 1306531950 
020 |a 3527682376  |q (Mobi) 
020 |a 9783527682379  |q (Mobi) 
020 |a 3527682368  |q (ePub) 
020 |a 9783527682362  |q (ePub) 
020 |z 9783527332199 
020 |z 9783527682379  |q (Mobi) 
020 |z 9783527682362  |q (ePub) 
029 1 |a CHBIS  |b 010259738 
029 1 |a CHVBK  |b 325940886 
029 1 |a DEBBG  |b BV042795782 
029 1 |a DEBBG  |b BV042989481 
029 1 |a DEBSZ  |b 431651620 
029 1 |a DEBSZ  |b 449419991 
029 1 |a GBVCP  |b 814301746 
029 1 |a DEBSZ  |b 475023528 
029 1 |a DEBBG  |b BV043396710 
035 |a (OCoLC)878141373  |z (OCoLC)874321908  |z (OCoLC)881423826  |z (OCoLC)961577287  |z (OCoLC)962694307 
037 |a 584446  |b MIL 
050 4 |a QP609.C92  |b .P467 2014eb 
060 4 |a QU 136 
072 7 |a MED  |x 075000  |2 bisacsh 
072 7 |a SCI  |x 036000  |2 bisacsh 
082 0 4 |a 612.01519  |2 23 
049 |a MAIN 
245 0 0 |a Phosphodiesterases and their inhibitors /  |c edited by Spiros Liras and Andrew S. Bell. 
264 1 |a Weinheim an der Bergstrasse, Germany :  |b Wiley-VCH,  |c 2014. 
264 4 |c ©2014 
300 |a 1 online resource (238 pages) :  |b illustrations. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
490 1 |a Methods and Principles in Medicinal Chemistry ;  |v Volume 61 
504 |a Includes bibliographical references at the end of each chapters and index. 
588 0 |a Print version record. 
505 0 |a Phosphodiesterases and Their Inhibitors; Contents; List of Contributors; Preface; A Personal Foreword; 1 Introduction; 2 Toward a New Generation of PDE5 Inhibitors through Advances in Medicinal Chemistry; 2.1 Introduction; 2.2 The First-Generation Agents; 2.3 PDE5 as a Mechanism and Alternative Indications Beyond MED; 2.4 A Summary of PDE5 Chemotypes Reported Post-2010; 2.5 Second-Generation PDE5 Inhibitors from Pfizer: Pyrazolopyrimidines; 2.6 Second-Generation PDE5 Inhibitors from Pfizer: Pyridopyrazinones; 2.7 Conclusions; References. 
505 8 |a 3 PDE4: New Structural Insights into the Regulatory Mechanism and Implications for the Design of Selective Inhibitors3.1 Introduction; 3.2 Isoforms, Domain Organization, and Splice Variants; 3.3 Structural Features of the Catalytic Site; 3.4 Regulation of PDE4 Activity; 3.5 Crystal Structure of Regulatory Domains of PDE4; 3.6 UCR2 Interaction and Selectivity; 3.7 Conclusions; References; 4 PDE4: Recent Medicinal Chemistry Strategies to Mitigate Adverse Effects; 4.1 Introduction; 4.2 Brief Summary of pan-PDE4 Inhibitors; 4.2.1 Rolipram; 4.2.2 Roflumilast; 4.2.3 Cilomilast; 4.2.4 Apremilast. 
505 8 |a 4.3 PDE4 Strategies to Avoid Gastrointestinal Events4.3.1 Allosteric Modulation; 4.3.2 PDE4D Selectivity; 4.3.3 Pfizer; 4.3.4 Novartis; 4.3.5 Merck-Frosst; 4.3.6 GEBR-7b; 4.3.7 PDE4B Selectivity; 4.3.8 Asahi Kasei; 4.3.9 GlaxoSmithKline; 4.3.10 Pfizer; 4.3.11 Tissue Targeting; 4.3.12 Polypharmacology; 4.3.13 Olanzapine Derivatives; 4.4 Conclusions; References; 5 The Function, Enzyme Kinetics, Structural Biology, and Medicinal Chemistry of PDE10A; 5.1 Enzymology and Protein Structure; 5.2 Papaverine-Related PDE10A Inhibitors; 5.3 MP-10/PF-2545920 Class of Inhibitors. 
505 8 |a 5.4 PF-2545920/MP-Inspired Inhibitors5.5 PF-2545920/Papaverine/Quinazoline Hybrid Series of Inhibitors; 5.6 PET Ligand Development; 5.7 Summary and Future; References; 6 The State of the Art in Selective PDE2A Inhibitor Design; 6.1 Introduction; 6.2 Selective PDE2A Inhibitors; 6.2.1 Bayer; 6.2.2 Altana AG; 6.2.3 Biotie Therapies; 6.2.4 Boehringer Ingelheim; 6.2.5 Janssen; 6.2.6 Lundbeck; 6.2.7 Merck; 6.2.8 Neuro3d; 6.2.9 Pfizer; 6.3 Methods; 6.4 Conclusions; References; 7 Crystal Structures of Phosphodiesterase 9A and Insight into Inhibitor Discovery; 7.1 Introduction. 
505 8 |a 7.2 Subtle Asymmetry of the PDE9 Dimer in the Crystals7.3 The Structure of the PDE9 Catalytic Domain; 7.4 Interaction of Inhibitors with PDE9; 7.5 Implication on Inhibitor Selectivity; References; 8 PDEs as CNS Targets: PDE9 Inhibitors for Cognitive Deficit Diseases; 8.1 PDE9A Enzymology and Pharmacology; 8.2 Crystal Structures of PDE9A Inhibitors; 8.3 Medicinal Chemistry Efforts toward Identifying PDE9A Inhibitors for Treating Cognitive Disorders; 8.3.1 Bayer; 8.3.2 Pfizer; 8.3.3 Boehringer Ingelheim; 8.3.4 Sun Yat-Sen University, China; 8.3.5 Envivo Pharmaceuticals. 
650 0 |a Cyclic nucleotide phosphodiesterases. 
650 0 |a Phosphodiesterases  |x Inhibitors. 
650 0 |a Phosphodiesterases  |x Inhibitors  |x Therapeutic use. 
650 4 |a Cyclic nucleotide phosphodiesterases. 
650 4 |a Nucleotides, Cyclic  |x physiology. 
650 4 |a Phosphodiesterase Inhibitors  |x therapeutic use. 
650 4 |a Phosphoric Diester Hydrolases  |x physiology. 
650 4 |a Phosphoric Diester Hydrolases. 
650 7 |a MEDICAL  |x Physiology.  |2 bisacsh 
650 7 |a SCIENCE  |x Life Sciences  |x Human Anatomy & Physiology.  |2 bisacsh 
650 1 2 |a Phosphodiesterase Inhibitors  |x chemistry. 
650 2 2 |a Phosphodiesterase Inhibitors  |x therapeutic use. 
655 4 |a Electronic books. 
700 1 |a Liras, Spiros,  |e editor. 
700 1 |a Bell, Andrew S.,  |e editor. 
776 0 8 |i Print version:  |t Phosphodiesterases and their inhibitors.  |d Weinheim an der Bergstrasse, Germany : Wiley-VCH, ©2014  |h xviii, 218 pages  |k Methods and principles in medicinal chemistry ; Volume 61  |z 9783527332199 
830 0 |a Methods and principles in medicinal chemistry ;  |v Volume 61. 
856 4 0 |u https://doi.org/10.1002/9783527682348  |z Full Text via HEAL-Link 
994 |a 92  |b DG1 

Παρόμοια τεκμήρια